KR102586736B1 - 헌팅틴을 단백질 영상화하기 위한 프로브 - Google Patents

헌팅틴을 단백질 영상화하기 위한 프로브 Download PDF

Info

Publication number
KR102586736B1
KR102586736B1 KR1020227035965A KR20227035965A KR102586736B1 KR 102586736 B1 KR102586736 B1 KR 102586736B1 KR 1020227035965 A KR1020227035965 A KR 1020227035965A KR 20227035965 A KR20227035965 A KR 20227035965A KR 102586736 B1 KR102586736 B1 KR 102586736B1
Authority
KR
South Korea
Prior art keywords
pyridin
methoxy
benzoxazol
methyl
methoxypyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227035965A
Other languages
English (en)
Korean (ko)
Other versions
KR20220148298A (ko
Inventor
셀리아 도밍게즈
존 휘트약
조나단 바드
알렉스 키셀료프
크리스토퍼 존 브라운
세바스티앙 르네 가브리엘 갈란
마이클 에드워드 프라임
폴 리차드 자일스
엘리스 루시넨 폴렛 가돌로
토마스 마틴 크룰
다니엘 클락-프류
피터 데이비드 존슨
사무엘 코
사라 헤이즈
Original Assignee
씨에이치디아이 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨에이치디아이 파운데이션, 인코포레이티드 filed Critical 씨에이치디아이 파운데이션, 인코포레이티드
Publication of KR20220148298A publication Critical patent/KR20220148298A/ko
Application granted granted Critical
Publication of KR102586736B1 publication Critical patent/KR102586736B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020227035965A 2014-08-29 2015-08-28 헌팅틴을 단백질 영상화하기 위한 프로브 Active KR102586736B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462043603P 2014-08-29 2014-08-29
US62/043,603 2014-08-29
KR1020177008383A KR102456946B1 (ko) 2014-08-29 2015-08-28 헌팅틴을 단백질 영상화하기 위한 프로브
PCT/US2015/047407 WO2016033445A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177008383A Division KR102456946B1 (ko) 2014-08-29 2015-08-28 헌팅틴을 단백질 영상화하기 위한 프로브

Publications (2)

Publication Number Publication Date
KR20220148298A KR20220148298A (ko) 2022-11-04
KR102586736B1 true KR102586736B1 (ko) 2023-10-11

Family

ID=55400648

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227035965A Active KR102586736B1 (ko) 2014-08-29 2015-08-28 헌팅틴을 단백질 영상화하기 위한 프로브
KR1020177008383A Active KR102456946B1 (ko) 2014-08-29 2015-08-28 헌팅틴을 단백질 영상화하기 위한 프로브

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177008383A Active KR102456946B1 (ko) 2014-08-29 2015-08-28 헌팅틴을 단백질 영상화하기 위한 프로브

Country Status (20)

Country Link
US (3) US10479802B2 (enExample)
EP (2) EP3186233B8 (enExample)
JP (2) JP6817207B2 (enExample)
KR (2) KR102586736B1 (enExample)
CN (2) CN116655618B (enExample)
AU (1) AU2015308774B2 (enExample)
BR (1) BR112017004141B8 (enExample)
CA (1) CA2959501C (enExample)
DK (1) DK3186233T3 (enExample)
EA (1) EA035646B1 (enExample)
ES (1) ES2898965T3 (enExample)
HR (1) HRP20211778T1 (enExample)
HU (1) HUE056957T2 (enExample)
IL (1) IL250803B (enExample)
MX (2) MX380810B (enExample)
PL (1) PL3186233T3 (enExample)
PT (1) PT3186233T (enExample)
SG (1) SG11201701600QA (enExample)
SI (1) SI3186233T1 (enExample)
WO (1) WO2016033445A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186241T (pt) 2014-08-29 2021-01-08 Chdi Foundation Inc Sondas para imagística de proteína de huntington
CA2959501C (en) 2014-08-29 2023-10-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
KR102410733B1 (ko) 2014-08-29 2022-06-20 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질을 영상화하기 위한 프로브
RU2721419C2 (ru) 2015-08-28 2020-05-19 СиЭйчДиАй ФАУНДЕЙШН, ИНК. Зонды визуализации белка гентингтина
RU2766139C2 (ru) 2016-03-11 2022-02-08 Ац Иммуне Са Бициклические соединения для диагностики и лечения
CN107056723A (zh) * 2017-04-21 2017-08-18 云南大学 一种具有抑制血管内皮生长因子受体信号传导的化合物
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
WO2019201921A1 (de) 2018-04-20 2019-10-24 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
SG11202012150UA (en) 2018-06-08 2021-01-28 Ac Immune Sa Novel compounds for diagnosis
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CN111635400A (zh) 2019-03-02 2020-09-08 察略盛医药科技(上海)有限公司 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
US11992535B2 (en) * 2019-12-18 2024-05-28 Chdi Foundation, Inc. Compounds and probes for imaging huntingtin protein
CN115209952B (zh) 2020-01-13 2025-05-30 维基分析有限公司 经取代的吡唑并嘧啶及其用途
CA3175602A1 (en) 2020-05-07 2021-11-11 Jerome Molette Novel compounds for diagnosis
US12036292B2 (en) * 2020-08-06 2024-07-16 Chdi Foundation, Inc. Heterobiaryl compounds and imaging agents for imaging huntingtin protein
CN117412960A (zh) * 2021-04-08 2024-01-16 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的异吲哚啉酮化合物和显像剂
CN117545512A (zh) * 2021-04-27 2024-02-09 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的氘化化合物和成像剂
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
US20250034149A1 (en) 2021-11-10 2025-01-30 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
AU2022385416A1 (en) 2021-11-10 2024-05-02 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
US20250042905A1 (en) 2021-11-10 2025-02-06 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
TW202425965A (zh) 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
EP4634191A1 (en) 2022-12-16 2025-10-22 AC Immune SA Novel compounds for diagnosis
WO2024126840A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
TW202500134A (zh) * 2023-05-18 2025-01-01 美商恩維達醫療公司 G-蛋白偶聯受體之拮抗劑
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same
CN119264072B (zh) * 2024-12-06 2025-05-02 国科大杭州高等研究院 对细胞成像的荧光探针及其合成方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524864A (ja) 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985755A (en) 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
US4198416A (en) 1976-09-30 1980-04-15 Meiji Seika Kaisha, Ltd. 5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters
DE2909754A1 (de) * 1979-03-13 1980-09-18 Thomae Gmbh Dr K Neue benzofuran- und benzothiophenderivate, deren herstellung und deren verwendung als arzneimittel
FR2524468B1 (fr) 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
PT729956E (pt) 1995-02-28 2002-03-28 Lilly Co Eli Compostos intermediarios formulacoes e metodos de benzotiofeno
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
EP0880519B1 (en) 1996-01-22 2002-04-17 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
JPH11171886A (ja) 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
EP1452530A4 (en) * 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
IL162243A0 (en) 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
AU2003304416A1 (en) 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
CN101384555A (zh) 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基二氢异喹啉酮类、其制备方法以及其作为药物的用途
BRPI0716583A2 (pt) * 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
JP5190893B2 (ja) * 2006-12-25 2013-04-24 国立大学法人東北大学 ベンゾキサゾール誘導体
US7858803B2 (en) * 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
WO2009042907A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
US20110076230A1 (en) * 2008-05-30 2011-03-31 Barrow James C Novel Substituted Indoles
WO2010051196A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
PL2414369T3 (pl) 2009-04-02 2016-04-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Pochodne imidazo[2,1-b][1,3,4]tiadiazolu
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
WO2012007510A1 (en) * 2010-07-14 2012-01-19 Bayer Pharma Aktiengesellschaft Compounds for binding and imaging amyloid plaques and their use
JP5824517B2 (ja) 2010-11-30 2015-11-25 武田薬品工業株式会社 二環性化合物
CN102391260B (zh) * 2011-09-29 2014-12-10 上海交通大学 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途
SG11201406759YA (en) * 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9370588B2 (en) * 2013-01-04 2016-06-21 University Of Massachusetts Luciferin amides
GB201306248D0 (en) * 2013-04-05 2013-05-22 Ucl Business Plc Compounds and their uses
CA2917267C (en) * 2013-07-17 2021-12-28 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
CA2959501C (en) * 2014-08-29 2023-10-10 Chdi Foundation, Inc. Probes for imaging huntingtin protein
KR102410733B1 (ko) 2014-08-29 2022-06-20 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질을 영상화하기 위한 프로브
US10907197B2 (en) 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186241T (pt) 2014-08-29 2021-01-08 Chdi Foundation Inc Sondas para imagística de proteína de huntington
RU2721419C2 (ru) 2015-08-28 2020-05-19 СиЭйчДиАй ФАУНДЕЙШН, ИНК. Зонды визуализации белка гентингтина

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524864A (ja) 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール

Also Published As

Publication number Publication date
CN116655618A (zh) 2023-08-29
MX380810B (es) 2025-03-12
JP7126541B2 (ja) 2022-08-26
AU2015308774B2 (en) 2020-03-19
EA035646B1 (ru) 2020-07-21
SI3186233T1 (sl) 2022-04-29
BR112017004141B8 (pt) 2022-08-02
EA201790407A1 (ru) 2017-08-31
MX2021003311A (es) 2021-05-14
BR112017004141A2 (pt) 2017-12-12
PL3186233T3 (pl) 2022-02-28
DK3186233T3 (da) 2021-11-22
AU2015308774A8 (en) 2017-03-23
US20230212190A1 (en) 2023-07-06
CN107108534B (zh) 2023-05-09
EP4006016A3 (en) 2022-11-16
CN116655618B (zh) 2025-12-05
JP2017528519A (ja) 2017-09-28
IL250803B (en) 2021-06-30
EP3186233A4 (en) 2018-05-30
HUE056957T2 (hu) 2022-04-28
US20170283436A1 (en) 2017-10-05
CA2959501C (en) 2023-10-10
US12258355B2 (en) 2025-03-25
US10479802B2 (en) 2019-11-19
WO2016033445A1 (en) 2016-03-03
MX2017002703A (es) 2018-01-16
US11059836B2 (en) 2021-07-13
KR20170046173A (ko) 2017-04-28
US20200102328A1 (en) 2020-04-02
KR102456946B1 (ko) 2022-10-21
ES2898965T3 (es) 2022-03-09
CA2959501A1 (en) 2016-03-03
HRP20211778T1 (hr) 2022-03-18
CN107108534A (zh) 2017-08-29
KR20220148298A (ko) 2022-11-04
JP6817207B2 (ja) 2021-01-20
PT3186233T (pt) 2021-12-02
AU2015308774A1 (en) 2017-03-16
SG11201701600QA (en) 2017-03-30
EP3186233B8 (en) 2021-09-29
EP3186233A1 (en) 2017-07-05
EP4006016A2 (en) 2022-06-01
JP2021059576A (ja) 2021-04-15
EP3186233B1 (en) 2021-08-25
IL250803A0 (en) 2017-04-30
BR112017004141B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
KR102586736B1 (ko) 헌팅틴을 단백질 영상화하기 위한 프로브
US12036291B2 (en) Probes for imaging huntingtin protein
EP3190888B1 (en) Probes for imaging huntingtin protein
KR102410733B1 (ko) 헌팅틴 단백질을 영상화하기 위한 프로브
US10137211B2 (en) Probes for imaging Huntingtin protein
HK1240583B (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221017

Application number text: 1020177008383

Filing date: 20170327

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230102

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230703

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231004

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231005

End annual number: 3

Start annual number: 1

PG1601 Publication of registration